An interventional study of Intrathecal morphine and Saline solution (placebo) in Labor Pain, sponsored by Samuel Lunenfeld Research Institute, Mount Sinai Hospital. Recruiting at 1 site in Canada. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-01.
Sponsored by Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Labor Pain by Samuel Lunenfeld Research Institute, Mount Sinai Hospital — 3 open to participants now, 3 under way, none of them phase 3. Labor Pain · Samuel Lunenfeld Research Institute, Mount Sinai Hospital.
Among the 22 studies in Labor Pain by Samuel Lunenfeld Research Institute, Mount Sinai Hospital, this one is the 3rd largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2024, is one of 15 with no phase, and was the 20th registered.
426 studies on the registry are indexed under Labor Pain; 76 are open to participants now.
Browse Labor Pain studies →3 of the 22 studies in Labor Pain by Samuel Lunenfeld Research Institute, Mount Sinai Hospital are open now, in 1 country. Recruiting first, the newest first:
Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Sites in Canada
Ages 18–55 · Women only · Healthy volunteers
Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Sites in Canada
Ages 18–50 · Women only · Healthy volunteers
By country, each count listing its studies:
Of the 31 Labor Pain studies recruiting now, 8 (26%) set no upper age limit and 23 (74%) stop at 75 or younger; 3 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 50 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 182 is above the median of 100 across 349 interventional studies indexed under Labor Pain.
Median enrollment 40 across the 15 interventional studies, 30 across the 7 observational. Of the 19 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Samuel Lunenfeld Research Institute, Mount Sinai Hospital is the lead sponsor of 138 studies on the registry; 17 are open to participants now.
2 of the studies in Labor Pain by Samuel Lunenfeld Research Institute, Mount Sinai Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06572241Samuel Lunenfeld Research Institute, Mount Sinai HospitalQuality of Labour Epidural Analgesia With Intrathecal Morphine as a Component of Combined Spinal Epidural | 2026-12 |
| NCT07516171Samuel Lunenfeld Research Institute, Mount Sinai HospitalA Digital Educational Resource to Improve Preparedness for Shared Decision Making About Labour Analgesia | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies in Labor Pain by Samuel Lunenfeld Research Institute, Mount Sinai Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Neuraxial analgesia has shown to be the gold standard for effective labor pain relief, offering numerous benefits including enhanced pain control and maternal satisfaction. The methods to achieve neuraxial analgesia include lumbar epidural (LE), and combined spinal epidural (CSE). While LE may not consistently provide optimal pain relief, leading to frequent maternal requests for supplemental analgesics, CSE presents a promising advancement. This is due to the rapid onset of pain relief from intrathecal components, complemented by the longer-lasting effects of epidural medications. Intrathecal drugs have demonstrated the ability to offer more symmetrical blockades compared to epidurally administered medications. Nonetheless, some clinicians remain cautious about CSE due to the potential for increased pain when transitioning from spinal to less effective epidural analgesia. Long-acting opioids like morphine in the intrathecal space may mitigate this problem by providing transitional analgesia to the laboring parturient.
The primary aim of this randomized controlled trial is to provide evidence of whether the addition of 100 mcg of morphine in the intrathecal (spinal) component of CSE reduces the rate of breakthrough pain during labor.
The addition of morphine to a combination of bupivacaine and lipophilic opioids (fentanyl) for the spinal component of CSE for labor analgesia has been shown to increase the duration of analgesia. A meta-analysis by Al-Kazwini and coworkers suggests a possible beneficial prolonging effect of adding morphine to spinal analgesia, however, the authors concluded that more adequately powered randomized controlled trials (RCTs) are required to determine the benefits and harms of intrathecal morphine (ITM).
This prolonged duration of action of ITM may reduce the need for frequent top-ups, which could alleviate nursing and anesthesiologist workload and enhance maternal satisfaction. An RCT conducted by Vasudevan and coworkers has concluded that the addition of 100 mcg ITM along with bupivacaine and fentanyl reduced the incidence of breakthrough pain in labor. Another dose-finding study comparing 50 and 100 mcg of ITM as a component of CSE labor analgesia concluded that 100 mcg of ITM significantly lowers the local anesthetic consumption and shorter duration of the first stage of labor without any significant difference in adverse effects. The RCT by Vasudevan et al. had a small sample size, enrolled mixed parity patients, and utilized continuous infusion for labor analgesia maintenance.
Hence, the investigators plan to conduct adequately powered RCT enrolling only primigravidae patients, which tend to have more prolonged labor than multiparous and programmed intermittent epidural bolus (PIEB) with patient-controlled epidural analgesia (PCEA) will be used, which is a more contemporary labor maintenance technique.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.6 ml of 0.25% bupivacaine, fentanyl 10 mcg with morphine 100 mcg (total volume 1 ml) as intrathecal component of combined spinal epidural (CSE).
Drug: Intrathecal morphine
0.6 ml of 0.25% bupivacaine, fentanyl 10 mcg with normal saline 0.2 ml (total volume 1 ml) as intrathecal component of combined spinal epidural (CSE).
Other: Saline solution (placebo)
morphine 100 mcg, included in the intrathecal component of combined spinal epidural (CSE).
Also known as: Morphine
normal saline 0.2 ml added to the intrathecal component of combined spinal epidural (CSE).
Also known as: saline
Presence of breakthrough pain: questionnaire
The rate of breakthrough pain is defined as the ratio of the number of episodes of breakthrough pain during labour analgesia and the duration of epidural analgesia. An episode of breakthrough pain during labour analgesia was defined as subjective discomfort due to pain or pressure increasing during a contraction (rated as NRS ≥3/10), which was successfully treated with the manual administration of supplemental medications.
Time frame: 24 hours
Time to first episode of breakthrough pain in minutes
The amount of time in minutes to the first recorded episode of breakthrough pain, defined as subjective discomfort due to pain or pressure increasing during a contraction (rated as NRS ≥3/10), which was successfully treated with the manual administration of supplemental medications.
Time frame: 24 hours
Epidural medication consumption (milliliters)
The overall consumption of epidural medication throughout labour, in milliliters.
Time frame: 24 hours
Epidural pump settings: questionnaire
Any adjustments made to the programmed intermittent bolus settings of the epidural pump will be recorded.
Time frame: 24 hours
Presence of fetal heart rate anomalies: questionnaire
The presence of any fetal heart rate anomalies will be recorded
Time frame: 24 hours
Presence of Cesarean delivery: questionnaire
The presence of Cesarean delivery will be recorded
Time frame: 24 hours
Analgesic consumption post-delivery: questionnaire
Presence of analgesic consumption post-delivery will be recorded.
Time frame: 24 hours
Presence of pruritis: questionnaire
The presence of pruritis (yes or no) will be recorded.
Time frame: 24 hours
Presence of nausea: questionnaire
The presence of nausea(yes or no) will be recorded.
Time frame: 24 hours
Presence of vomiting: questionnaire
The presence of vomiting(yes or no) will be recorded.
Time frame: 24 hours
Presence of sedation: questionnaire
The presence of sedation(yes or no) will be recorded.
Time frame: 24 hours
Presence of respiratory depression: questionnaire
The presence of respiratory depression(yes or no) will be recorded.
Time frame: 24 hours
Apgar score at 1 minute
Apgar score recorded by the respiratory therapist, nurse or midwife at 1 minute of life.
Time frame: 1 minute
Apgar score at 5 minutes
Apgar score recorded by the respiratory therapist, nurse or midwife at 5 minutes of life.
Time frame: 5 minutes
Umbilical artery pH
Lab results for umbilical artery pH
Time frame: 24 hours
Umbilical vein pH
Lab results for umbilical vein pH
Time frame: 24 hours
Satisfaction: questionnaire
Post-delivery, patients will be asked how satisfied they were with their labour analgesia from 0-10, where 0 is no pain and 10 is the worst pain imaginable.
Time frame: 24 hours
Obstetric Quality of Recovery-10 (ObsQoR-10) score 24 hours
ObsQoR-10 score at 24 hours. There are 10 questions, and the results are tabulated out of 100. The higher the overall score out of 100, the better quality of recovery a patient is experiencing.
Time frame: 24 hours
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Dec 2026, 25 months after the start.
Of 192 non-industry interventional studies with no phase under Labor Pain, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's planned 25 months is above that.
Counting every sponsor, half of 194 studies reached it within 9 months; a quarter within 5 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Morphine
Samuel Lunenfeld Research Institute, Mount Sinai Hospital →